C4 Therapeutics Cash And Equivalents vs. Total Debt
| CCCC Stock | USD 4.71 0.40 9.28% |
For C4 Therapeutics profitability analysis, we use financial ratios and fundamental drivers that measure the ability of C4 Therapeutics to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well C4 Therapeutics utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between C4 Therapeutics's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of C4 Therapeutics over time as well as its relative position and ranking within its peers.
CCCC |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of C4 Therapeutics. If investors know CCCC will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about C4 Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.71) | Revenue Per Share 0.522 | Quarterly Revenue Growth 0.387 | Return On Assets (0.21) | Return On Equity (0.46) |
The market value of C4 Therapeutics is measured differently than its book value, which is the value of CCCC that is recorded on the company's balance sheet. Investors also form their own opinion of C4 Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is C4 Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because C4 Therapeutics' market value can be influenced by many factors that don't directly affect C4 Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between C4 Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if C4 Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, C4 Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
C4 Therapeutics Total Debt vs. Cash And Equivalents Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining C4 Therapeutics's current stock value. Our valuation model uses many indicators to compare C4 Therapeutics value to that of its competitors to determine the firm's financial worth. C4 Therapeutics is rated below average in cash and equivalents category among its peers. It is rated third in total debt category among its peers making up about 0.23 of Total Debt per Cash And Equivalents. The ratio of Cash And Equivalents to Total Debt for C4 Therapeutics is roughly 4.34 . The current year's Total Debt To Capitalization is expected to grow to 0.24. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the C4 Therapeutics' earnings, one of the primary drivers of an investment's value.CCCC Total Debt vs. Cash And Equivalents
Cash or Cash Equivalents are the most liquid of all assets found on the company's balance sheet. It is used in calculating many of the firm's liquidity ratios and is a good indicator of the overall financial health of a company. Companies with a lot of cash are usually attractive takeover targets. Cash Equivalents are balance sheet items that are typically reported using currency printed on notes.
C4 Therapeutics |
| = | 307.78 M |
Cash equivalents represent current assets that are easily convertible to cash such as short term bonds, savings account, money market funds, or certificate of deposits (CDs). One of the important consideration companies make when classifying assets as cash equivalent is that investments they report on their balance sheets under current assets should have almost no risk of change in value over the next few months (usually three months).
Total Debt refers to the amount of long term interest-bearing liabilities that a company carries on its balance sheet. That may include bonds sold to the public, notes written to banks or capital leases. Typically, debt can help a company magnify its earnings, but the burden of interest and principal payments will eventually prevent the firm from borrow excessively.
C4 Therapeutics |
| = | 70.98 M |
In most industries, total debt may also include the current portion of long-term debt. Since debt terms vary widely from one company to another, simply comparing outstanding debt obligations between different companies may not be adequate. It is usually meant to compare total debt amounts between companies that operate within the same sector.
CCCC Total Debt vs Competition
C4 Therapeutics is rated third in total debt category among its peers. Total debt of Health Care industry is currently estimated at about 460.73 Million. C4 Therapeutics retains roughly 70.98 Million in total debt claiming about 15% of equities under Health Care industry.
C4 Therapeutics Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in C4 Therapeutics, profitability is also one of the essential criteria for including it into their portfolios because, without profit, C4 Therapeutics will eventually generate negative long term returns. The profitability progress is the general direction of C4 Therapeutics' change in net profit over the period of time. It can combine multiple indicators of C4 Therapeutics, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
| Last Reported | Projected for Next Year | ||
| Accumulated Other Comprehensive Income | -127 K | -133.3 K | |
| Net Interest Income | 6.6 M | 6.9 M | |
| Interest Income | 8.6 M | 9 M | |
| Operating Income | -139 M | -132.1 M | |
| Net Loss | -134.9 M | -128.2 M | |
| Income Before Tax | -131.2 M | -124.7 M | |
| Total Other Income Expense Net | 7.8 M | 8.2 M | |
| Net Loss | -115.4 M | -109.6 M | |
| Net Loss | -132.5 M | -125.9 M | |
| Income Tax Expense | 1.3 M | 1.3 M | |
| Non Operating Income Net Other | -2.3 M | -2.4 M | |
| Change To Netincome | 34.5 M | 36.2 M | |
| Net Loss | (2.67) | (2.80) | |
| Income Quality | 0.81 | 0.42 | |
| Net Income Per E B T | 1.01 | 1.11 |
CCCC Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on C4 Therapeutics. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of C4 Therapeutics position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the C4 Therapeutics' important profitability drivers and their relationship over time.
Use C4 Therapeutics in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if C4 Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in C4 Therapeutics will appreciate offsetting losses from the drop in the long position's value.C4 Therapeutics Pair Trading
C4 Therapeutics Pair Trading Analysis
The ability to find closely correlated positions to C4 Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace C4 Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back C4 Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling C4 Therapeutics to buy it.
The correlation of C4 Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as C4 Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if C4 Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for C4 Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your C4 Therapeutics position
In addition to having C4 Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Broad Equity ETFs Thematic Idea Now
Broad Equity ETFs
ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The Broad Equity ETFs theme has 483 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Broad Equity ETFs Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Trending Equities. For information on how to trade CCCC Stock refer to our How to Trade CCCC Stock guide.You can also try the Top Crypto Exchanges module to search and analyze digital assets across top global cryptocurrency exchanges.
To fully project C4 Therapeutics' future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of C4 Therapeutics at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include C4 Therapeutics' income statement, its balance sheet, and the statement of cash flows.